Rational Pharmacotherapy in Cardiology

Advanced search

The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial

Full Text:


The aim of this review was to present the recently published results of ODYSSEY OUTCOMES trial and discuss the clinical perspective of these data. Patients with acute coronary syndrome are at very high risk of recurrent ischemic cardiovascular complications, especially during the first year after the event. The use of high-intensity statin therapy in this group of patients does not always lead to the achievement of target levels of atherogenic lipoproteins. PCSK9 inhibitors, administered in addition to statins, can provide additional reduction of low-density lipoprotein cholesterol, which leads to further improvements of outcomes in patients with atherosclerotic cardiovascular disease. According to the latest results from ODYSSEY OUTCOMES trial, among patients with recent acute coronary syndrome, who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who were treated with alirocumab then among those who received placebo. The treatment with alirocumab in patients with recent acute coronary syndrome was associated with reduction in death from any causes. The absolute risk reduction with alirocumab was the most prominent in the subpopulation of patients with low-density lipoprotein cholesterol ≥2,6 mmol/l at baseline. These results have implication for clinical practice and may play an important role for the improvement of outcomes in patients at highest cardiovascular risk after acute cardiovascular syndrome.

About the Author

Yu. A. Karpov
National Medical Research Centre of Cardiology
Russian Federation
MD, PhD, Professor, Head of Department of Angiology


1. Ference B.A., Ginsberg H.N., Graham I., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72. doi:10.1093/eurheartj/ehx144.

2. Catapano A.L., Graham I., De Backer G., et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.Eur Heart J 2016;37(39):2999-3058. doi:10.1093/eurheartj/ehw272

3. Jernberg T., Hasvold P., Henriksson M., et al. Cardiovascular risk in post-myocardial infarction patients: nationwide realworld data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163-70. doi:10.1093/eurheartj/ehu505.

4. Abu-Assi E., López-López A., González-Salvado V., et al. The risk of cardiovascular events after an acute coronary event remains high, especially during the first year, despite revascularization. Rev Esp Cardiol (Engl Ed). 2016;69(1):11-18. doi:10.1016/j.rec.2015.06.015.

5. Stone G.W., Maehara A., Lansky A.J., et al. A Prospective Natural-History Study of Coronary Atherosclerosis. N Engl J Med 2011;364(3):226-235. doi:10.1056/NEJMoa1002358.

6. Maron D.J., Spertus, J.A., ManciniG.B., et al. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol. 2009;104(8):1055-62. doi:10.1016/j.amjcard.2009.05.056.

7. Jellinger P.S., Handelsman Y., Rosenblit P.D, et al. American Association of Clinical Endocrinologists and American Collegeof Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1-87. doi:10.4158/EP171764.APPGL.

8. Ezhov M.V., Sergienko I.V., Aronov D.M. et al. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Ateroskleroz i Dislipidemii. 2017;3:5-22. (In Russ.)

9. Zhao S., Wang Y., Mu Y., et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis. 2014; 235(2):463-9.doi:10.1016/j.atherosclerosis.2014.05.916

10. Reiner, Ž. De Backer G., Fras Z., et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries - findings from the EUROASPIRE IV survey. Atherosclerosis. 2016;246:243-50. doi:10.1016/j.atherosclerosis.2016.01.018.

11. Kotseva K. on behalf of EUROASPIRE investigators. Implementation of cardiovascular disease prevention in daily practice – Insights from EUROASPIRE V. Reaching lipid targets in coronary patents -Temporal trends and state of the art. Presented at ESC 2018, Munich. [cited by Nov 11, 2018]. Available from:

12. Gitt A.K., Drexel H., Feely J., et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prevent Cardiol. 2012;19:221-30. doi:10.1177/1741826711400545.

13. Nanchen D., Gencer B., Auer R., et al. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J. 2015;36(36):2438-45. doi:10.1093/eurheartj/ehv289.

14. Benn M., Watts G.F., Tybjaerg-Hansen A., et al. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97:3956-64.

15. Ezhov M.V., Lazareva N.V., Sagajdak O. V. et al. The frequency of lipid metabolism disorders and the use of statins in acute coronary syndrome (according to the Federal Register of Acute Coronary Syndrome). Ateroskleroz i Dislipidemii. 2018;1:47-57. (In Russ.)

16. Rallidis L.S., Triantafyllis A.S., Tsirebolos G., et al. Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins Atherosclerosis. 2016;249:17-21. doi:10.1016/j.atherosclerosis.2016.03.023.

17. Zhang H., Plutzky J., Skentzos S., et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526-34. doi:10.7326/0003-4819-158-7-201304020-00004.

18. Ganga H.V., Slim H.B., Thompson P.D. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6-15.doi:10.1016/j.ahj.2014.03.019.

19. Cohen J.D., Brinton E.A., Ito M.K., et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208-15. doi:10.1016/j.jacl.2012.03.003.

20. Serban M.C., Colantonio L.D., Manthripragada A.D., et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol. 2017;69(11):1386-95. doi:10.1016/j.jacc.2016.12.036.

21. Instructions for medical use of drug Prauent, solution for subcutaneous injection, 75 or 150 mg / ml, RU NO. LP-004078 (Sanofi-Aventis Group, France). [cited by Nov 10, 2018]. Available from: (In Russ.)

22. McKenney J.M., Koren M.J., Kereiakes D.J., et al. Safety and efficacy of a monoclonal antibody to proproteinconvertasesubtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344-53. doi:10.1016/j.jacc.2012.03.007.

23. Stein E.A., Gipe D., Bergeron J., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012; 380(9836):29-36. doi:10.1016/S0140-6736(12)60771-5.

24. Roth E.M., Taskinen M.R., Ginsberg H.N., et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol. 2014;176(1):55-61. doi:10.1016/j.ijcard.2014.06.049.

25. Moriarty P.M., Thompson P.D., Cannon C.P., et al. Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758-69. doi:10.1016/j.jacl.2015.08.006.

26. Stroes E., Guyton J.R., Farnier M., et al. for the ODYSSEY CHOICE II investigators. Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study. J Am Heart Assoc. 2016;5(9):e003421. doi:10.1161/JAHA.116.003421.

27. Teramoto T., Kobayashi M., Uno K., et al. Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies). Am J Cardiol. 2016;118(1):56-63. doi:10.1016/j.amjcard.2016.04.011.

28. Kastelein J.J., Ginsberg H.N., Langslet G., et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996-3003. doi:10.1093/eurheartj/ehv370.

29. Ginsberg H.N., Rader D.J., Raal F.J., et al. Efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Cardiovasc Drugs Ther. 2016;30(5):473-83. doi:10.1007/s10557-016-6685-y.

30. Robinson J.G., Farnier M., Krempf M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-99. doi:10.1056/NEJMoa1501031.

31. Kereiakes D.J., Robinson J.G., Cannon C.P., et al. Efficacy and safety of the proproteinconvertasesubtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906-915.e13. doi:10.1016/j.ahj.2015.03.004.

32. Cannon C.P., Cariou B., Blom D., et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186-94. doi:10.1093/eurheartj/ehv028.

33. Bays H., Gaudet D., Weiss R., et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015;100(8):3140-8. doi:10.1210/jc.2015-1520.

34. Farnier M., Jones P., Severance R., et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:138-46. doi:10.1016/j.atherosclerosis.2015.11.010.

35. Schwartz G.G., Steg P.G., Szarek M., et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-107. doi:10.1056/NEJMoa1801174.

36. Schwartz G.G. Szarek M.M., Bhatt D.L., et al. Alirocumab Reduces Risk of Death after Acute Coronary Syndrome in Patients with Persistently Elevated Atherogenic Lipoproteins on Intensive Statin Treatment. Presentation at American Heart Association Scientific Session (November 11, 2018), Chicago (Illinois), USA. [cited by Nov 10, 2018]. Available from:!/ 4682/presentation/59973.

37. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97.doi:10.1056/NEJMoa1410489.

38. Schwartz G.G., Olsson A.G., Abt M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-99. doi:10.1056/NEJMoa1206797.

39. Roth EM, Goldberg AC, Catapano AL, et al. Antidrug antibodies in patients treated with alirocumab. N Engl J Med. 2017;376:1589-90.

40. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504. doi:10.1056/NEJMoa040583.

41. Navarese E.P., Robinson J.G., Kowalewski M., et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018;319:1566-79. doi:10.1001/jama.2018.2525.

42. Sabatine M.S., Giugliaano R.P., Keech A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-22. doi:10.1056/NEJMoa1615664.

43. Ridker P.M., Revkin J., Amarenco P., et al. Cardiovascular efficacy and safety of bococizumab in highrisk patients. N Engl J Med. 2017;376:1527-39. doi:10.1056/NEJMoa1701488.

For citation:

Karpov Y.A. The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial. Rational Pharmacotherapy in Cardiology. 2018;14(6):922-934.

Views: 173

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)